Clinical trial CAEL101-302
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis
Cancers | |
---|---|
Organ | Amyloidose |
Trial status | Trial closed for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | Caelum Biosciences, Inc. |
EudraCT Identifier | 2020-000713-32 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04512235 |
Inclusion criteria | Mayo stage IIIa |
Last update |